Healthtech Series B Investors & VC Firms
1216 firms in this list, with a median first check of $750K. 285 of them lead rounds. Generated from verified public data and updated continuously.
3xP Global
LisbonSeries A–Series B$1.1M – $10.8M
3 people
Bios Partners
Fort WorthSeed–Growth
15 people
MassMutual Ventures
SpringfieldSeed–Growth$500K – $5M
6 people
TBT
SeoulPre-Seed–Late Stage
CVC Asia Pacific (Japan) Kabushiki Kaisha
TokyoSeries B–Late Stage
11 people
MemorialCare Innovation Fund
Long BeachSeed–Growth
11 people
Mérieux Equity Partners
ParisSeed–Late Stage$3.2M – $86M
11 people
Neulogy Ventures
LuxembourgPre-Seed–Growth$216K – $3.2M
5 people
Pureos Bioventures
PfäffikonSeed–Series C
11 people
Revo Capital
IstanbulPre-Seed–Series B$250K – $5M
2 people
FEMSA Ventures
Mexico CitySeed–Growth$500K – $5M
1 person
Droia Ventures
LeuvenPre-Seed–Series B$540K
7 people
Heran Partners
AntwerpSeed–Series B
12 people
K20 Fund
Valley StreamSeed–Growth$100K – $2.5M
3 people
Singular
ParisSeed–Series B
6 people
Braven
New YorkSeed–Series B
17 people
Criteria Bio Ventures
BarcelonaSeed–Late Stage
8 people
Dubai Future District Fund
DubaiPre-Seed–Late Stage
17 people
Reinventure Group
SydneySeed–Series B
5 people
Shaping Impact Group
BrusselsPre-Seed–Series B$270K – $1.6M
14 people
Solasta Ventures
BostonSeed–Series C
8 people
Union Grove Venture Partners
Chapel HillPre-Seed–Late Stage
2 people
APERTURE Venture Partners
BostonSeed–Series C$1M – $5M
4 people
Rocket Internet SE
BerlinSeed–Late Stage
10 people
Related lists
Series B Investors & VC Firms (4094)Healthtech Investors & VC Firms (3208)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Series B Investors & VC Firms in United States (1625)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)
Data sourced from public filings and firms' own websites — see our methodology.
































































